Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 26, 2018
Pharmacy Choice - News - Pharmaceutical Development - April 26, 2018

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/26/18 - 14501 - Polyaxial Pedicular Screw with Single Locking System, 6-7 Mm Diameter, Any Length, Titanium with Inne-Imported, Us Fda Approved, Make of Meditronics or Synthes or Zimmer only. 16038 - Polyaxial Pedicular Screw with Head and Locking, 4.0 Mm -
Ministry/Department Ministry of Railways Dr. Babasaheb Ambedekar Memorial Hospital, Central Railway Dr Ambedekar Road, Byculla East MUMBAI Attn: Md/Byculla-Medical/Central Rly. Description: Tenders are invited for 14501- Polyaxial Pedicular Screw with Single Locking System, 6-7 Mm Diameter, Any Length, Titanium with Inne-Imported, Us Fda Approved,
4/26/18 - Digestible Medical Sensors Market Highly Favorable to the Growth Rate by 2022: The globaldigestible medical sensors market is expected to witness a favorable growth during the forecast period.
Albany, NY 04/25/2018 Digestible Medical Sensor helps the doctor/caregiver get patient data on mobile application. Digestible Medical senor will be used for medical adherence and study vital signs. Digestible medical Sensor is a new technology in the market with recent FDA approval to market in United States and Europe.
4/26/18 - Further MP0250 Clinical Data and Partner Interest Underline Molecular Partners' Continued Progress of Its Proprietary Oncology Compounds
Bill Burns elected Chairman of Molecular Partners at the 2018 AGM on April 18 Talent base with 113 full-time employees, reflecting further build-out of oncology expertise. ZURICH- SCHLIEREN, SWITZERLAND/ ACCESSWIRE/ April 26, 2018/ Molecular Partners AG, a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin t
4/26/18 - GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO
GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that five abstracts were accepted at the 2018 Association for Research in Vision and Ophthalmology Annual Meeting in Honolulu, Hawaii, April 29 May 3,
4/26/18 - Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
By a News Reporter-Staff News Editor at Gene Therapy Weekly Pfizer Inc. has initiated a Phase 1 b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy. "On behalf of the community of individuals and families living with Duchenne muscular dystrophy, we applaud the important step Pfiz
4/26/18 - Saniona progress to second part of Phase 2a study for Tesomet in Prader-Willi Syndrome based on positive results in adult patients
Saniona, a leading biotech company in the field of ion channels, today announced that it has obtained approval to initiate the second part of its Phase 2 a trial for Tesomet in adolescents with Prader-Willi syndrome. By pursuing an orphan indication such as Prader-Willi syndrome, we may develop and commercialize our own product in the U.S. and Euro
4/26/18 - Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome
Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome. Glepaglutide is in development as a new treatment option for patients with short bowel syndrome The pivotal phase 3 trial is on track for initiation in Q3 2018 Copenhagen, Denmark, April 26, 2018- Zealand Pharma today announced receipt of the End-
4/25/18 - AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
AbbVie, a research-based global biopharmaceutical company, announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for risankizumab, an investigational interleukin-23 inhibitor, being evaluated for treatment of patients with moderate to severe plaque psoriasis. "The risankizumab submission represe
4/25/18 - AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients
AbbVie, a research-based global biopharmaceutical company, today announced positive results from the ongoing Phase 2 b/3 SELECT-SUNRISE clinical trial, showing that at 12 weeks, all doses of upadacitinib met the study's primary endpoint of ACR20 a versus placebo. 1 Certain key efficacy endpoints were also achieved versus placebo. 1 The study, con
4/25/18 - Acticor Biotech Announces That the European Medicines Agency Clears the Route for a Phase II of Its ACT017 Product in Stroke
Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, has discussed with the European Medicines Agency the development of its drug candidate, ACT017. This meeting follows the completion of the first-in-human study in January 2018 which provided preliminar
4/25/18 - ADC Therapeutics Announces the Termination of its ADCT-502 Program Targeting HER2 Expressing Solid Tumors
LAUSANNE, Switzerland ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates targeting major cancers, today announced that it has terminated the Phase I clinical trial to evaluate its antibody drug conjugate ADCT-502 in patients with advanced solid tumors
4/25/18 - Adult Diapers May No Longer Be Needed Thanks To Amazing New Pill
AHP- Adult diaper sales are expected to plummet as results from a clinical trial on a new, patented bladder control pill have finally been released. Sold under the brand name UriVarx?, the new pill contains key ingredients that keeps the bladder from releasing voluntarily, which reduces accidents and fretiuent bathroom trips. Bassam Damaj of Inno
4/25/18 - Alder BioPharmaceuticals Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine [T-break Tech (Middle East)]
Alder BioPharmaceuticals, Inc., a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new twelve-month data from its PROMISE 1 Phase 3 clinical trial in episodic migraine patients. Detailed results will be presented today at the 70th Annual American Academy of Neurology Meeting
4/25/18 - Alder BioPharmaceuticals New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals (Up to 32.5 days) and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine
Alder BioPharmaceuticals, Inc., a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new data from its PROMISE 1 Phase 3 clinical trial evaluating eptinezumab, Alder s lead investigational product candidate for migraine prevention, in patients with episodic migraine.
4/25/18 - Alder BioPharmaceuticals New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine
Alder BioPharmaceuticals, a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new data from its PROMISE 1 Phase 3 clinical trial evaluating eptinezumab, Alder s lead investigational product candidate for migraine prevention, in patients with episodic migraine.
4/25/18 - Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial [T-break Tech (Middle East)]
Aldeyra Therapeutics, Inc., a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that it has enrolled the first patient in a Phase 3 clinical trial of topical ocular reproxalap for the treatment of allergic conjunctivitis. "We are pleased to advance
4/25/18 - Align Technology Announces China Food and Drug Administration Approval for the iTero Element Intraoral Scanner
Align Technology, Inc. today announced that the company has received approval from the China Food and Drug Administration to market the iTero Element intraoral scanner in China.. The market opportunity in China is huge and it remains the single largest country market for Align outside of the United States, said Julie Tay, Align Technology s
4/25/18 - Alkahest Announces Initiation of Phase 2 Clinical Trial of GRF6019 in Alzheimer's Disease
Alkahest Inc., a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced the initiation of a Phase 2 randomized, double-blinded dose response study of GRF6019 in patients with mild to moderate Alzheimer's Disease. "The initiation of this study represents a significant milesto
4/25/18 - ANI Pharmaceuticals Announces Approval of Morphine Sulfate Oral Solution
BAUDETTE- ANI Pharmaceuticals, Inc. today announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Morphine Sulfate Oral Solution 10 mg/5mL, 20 mg/5mL and 100 mg/5mL. The current annual U.S. market for this product is approximately $17 million, according to Iqvia/IMS Health.
4/25/18 - Apexian Pharmaceuticals Dr. Mark Kelley Recognized as an Outstanding Researcher at Indiana University/Purdue University IUPUI
Apexian Pharmaceuticals, a clinical-stage biotechnology company focused on developing safe and effective therapy for patients with high unmet medical needs, is pleased to announce that its Chief Scientific Officer, Mark Kelley, PhD, was recognized as an outstanding scholar and researcher during the annual IUPUI Chancellor's Academic Honors...
4/25/18 - Ascendis Pharma A/S Announces Upcoming Investor Presentations
Ascendis Pharma A/S, a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical needs, today announced that the company will participate in two upcoming investor conferences in May.. A live audio webcast of these events will be available in the Investors and News section of the
4/25/18 - Asklepios BioPharmaceutical, Inc. Announces Former Portfolio Company's Preclinical Asset for Duchenne Muscular Dystrophy Has Advanced into the Clinic
Asklepios BioPharmaceutical, Inc., an advanced gene therapy platform company, today announced that a preclinical GT asset for Duchenne Muscular Dystrophy, initially developed by AskBio spin-out Bamboo Therapeutics, Inc. and a wholly-owned subsidiary of Pfizer Inc. since 2016, has advanced into the clinic. Pfizer announced April 12, 2018 the initi
4/25/18 - AstraZeneca - US FDA approves TAGRISSO as 1st-line treatment for EGFR-mutated non-small cell lung cancer
AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO for the 1st- line treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor mutations, as detected by an FDA- approved test. The approval is based on results from the Phase III FLAURA trial, which were
4/25/18 - AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-SymptomaticSMA Types 1, 2 and 3
AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that the first patient has been dosed in a Phase 3 trial evaluating AVXS-101 in pre-symptomatic patients with spinal muscular atrophy Types 1, 2 and 3.. Treating SMA as e
4/25/18 - AZs immuno-oncology combo fails another lung cancer trial [Tehran Times (Iran)]
Shares in AstraZeneca were on the slide this morning after its combination of Imfinzi and tremelimumab failed to hit the mark in a phase III lung cancer trial. Imfinzi picked up a valuable approval from the FDA in February as a monotherapy maintenance therapy for NSCLC patients with inoperable stage III disease, i.e. which has not spread widely aro
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415